Kim De Leeneer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kim De Leeneer has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Kathleen Bertha Michaël Claes
Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
8 shared publications - Bruce Poppe
Centre for Medical Genetics Gent (CMGG), Ghent University Hospital, Ghent, Belgium
5 shared publications - Dieter Deforce
Laboratory of Pharmaceutical Biotechnology, Ghent University, Ottergemsesteenweg 460, Gent, 9000, Belgium
3 shared publications - Anne Vral
Department of Human Structure and Repair, Radiobiology Lab, Ghent University
2 shared publications - Filip Pattyn
Center for Medical Genetics, Ghent University, Ghent, Belgium
2 shared publications - Filip Van Nieuwerburgh
Laboratory of Pharmaceutical Biotechnology, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
2 shared publications
Latest Publications
- Open Access
Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients
(1) Background: The proportion and spectrum of germline pathogenic variants (PV) associated with an increased risk for pancreatic ductal adenocarcinoma (PDAC) varies among populations. (2) Methods: We analyzed 72 Belgian and 226 Czech PDAC patients by multigene panel testing. The prevalence of pathogenic variants (PV) in relation to personal/family cancer history were evaluated. PDAC risks were calculated using both gnomAD-NFE and population-matched controls. (3) Results: In 35/298 (11.7%) patients a PV in an established PDAC-predisposition gene was found. BRCA1/2 PV conferred a high risk in both populations, ATM and Lynch genes only in the Belgian subgroup. PV in other known PDAC-predisposition genes were rarer. Interestingly, a high frequency of CHEK2 PV was observed in both patient populations. PV in PDAC-predisposition genes were more frequent in patients with (i) multiple primary cancers (12/38; 32%), (ii) relatives with PDAC (15/56; 27%), (iii) relatives with breast/ovarian/colorectal cancer or melanoma (15/86; 17%) but more rare in sporadic PDAC (5/149; 3.4%). PV in homologous recombination genes were associated with improved overall survival (HR = 0.51; 95% CI 0.34–0.77). (4) Conclusions: Our analysis emphasizes the value of multigene panel testing in PDAC patients, especially in individuals with a positive family cancer history, and underlines the importance of population-matched controls for risk assessment.
Open AccessPrevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients
(1) Background: The proportion and spectrum of germline pathogenic variants (PV) associated with an increased risk for pancreatic ductal adenocarcinoma (PDAC) varies among populations. (2) Methods: We analyzed 72 Belgian and 226 Czech PDAC patients by multigene panel testing. The prevalence of pathogenic variants (PV) in relation to personal/family cancer history were evaluated. PDAC risks were calculated using both gnomAD-NFE and population-matched controls. (3) Results: In 35/298 (11.7%) patients a PV in an established PDAC-predisposition gene was found. BRCA1/2 PV conferred a high risk in both populations, ATM and Lynch genes only in the Belgian subgroup. PV in other known PDAC-predisposition genes were rarer. Interestingly, a high frequency of CHEK2 PV was observed in both patient populations. PV in PDAC-predisposition genes were more frequent in patients with (i) multiple primary cancers (12/38; 32%), (ii) relatives with PDAC (15/56; 27%), (iii) relatives with breast/ovarian/colorectal cancer or melanoma (15/86; 17%) but more rare in sporadic PDAC (5/149; 3.4%). PV in homologous recombination genes were associated with improved overall survival (HR = 0.51; 95% CI 0.34–0.77). (4) Conclusions: Our analysis emphasizes the value of multigene panel testing in PDAC patients, especially in individuals with a positive family cancer history, and underlines the importance of population-matched controls for risk assessment.
- Open Access
Germline Genetic Findings Which May Impact Therapeutic Decisions in Families with a Presumed Predisposition for Hereditary Breast and Ovarian Cancer
In this study, we aim to gain insight in the germline mutation spectrum of ATM, BARD1, BRIP1, ERCC4, PALB2, RAD51C and RAD51D in breast and ovarian cancer families from Spain. We have selected 180 index cases in whom a germline mutation in BRCA1 and BRCA2 was previously ruled out. The importance of disease-causing variants in these genes lies in the fact that they may have possible therapeutic implications according to clinical guidelines. All variants were assessed by combined annotation dependent depletion (CADD) for scoring their deleteriousness. In addition, we used the cancer genome interpreter to explore the implications of some variants in drug response. Finally, we compiled and evaluated the family history to assess whether carrying a pathogenic mutation was associated with age at diagnosis, tumour diversity of the pedigree and total number of cancer cases in the family. Eight unequivocal pathogenic mutations were found and another fourteen were prioritized as possible causal variants. Some of these molecular results could contribute to cancer diagnosis, treatment selection and prevention. We found a statistically significant association between tumour diversity in the family and carrying a variant with a high score predicting pathogenicity (p = 0.0003).
Open AccessGermline Genetic Findings Which May Impact Therapeutic Decisions in Families with a Presumed Predisposition for Hereditary Breast and Ovarian Cancer
In this study, we aim to gain insight in the germline mutation spectrum of ATM, BARD1, BRIP1, ERCC4, PALB2, RAD51C and RAD51D in breast and ovarian cancer families from Spain. We have selected 180 index cases in whom a germline mutation in BRCA1 and BRCA2 was previously ruled out. The importance of disease-causing variants in these genes lies in the fact that they may have possible therapeutic implications according to clinical guidelines. All variants were assessed by combined annotation dependent depletion (CADD) for scoring their deleteriousness. In addition, we used the cancer genome interpreter to explore the implications of some variants in drug response. Finally, we compiled and evaluated the family history to assess whether carrying a pathogenic mutation was associated with age at diagnosis, tumour diversity of the pedigree and total number of cancer cases in the family. Eight unequivocal pathogenic mutations were found and another fourteen were prioritized as possible causal variants. Some of these molecular results could contribute to cancer diagnosis, treatment selection and prevention. We found a statistically significant association between tumour diversity in the family and carrying a variant with a high score predicting pathogenicity (p = 0.0003).
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB033
AB033. P003. Identification of germline mutations in cancer predisposition genes in patients with a personal and/or family history of pancreatic cancer
Background: Pancreatic cancer is estimated to have a familial background in 5–10%. Although the underlying genetic basis for most of the familial clustering remains elusive, multiple known hereditary syndromes and genes are associated with an increased risk of developing pancreatic cancer. Methods: We performed a retrospective genetic evaluation of 80 cancer patients with a presumed genetic predisposition for pancreatic cancer. The probands were selected from seven strata based on personal or family history of pancreatic cancer, breast and/or ovarian cancer, colon cancer or melanoma. Germline DNA was analyzed using a custom designed HEAT-Seq target panel of 52 (pancreatic) cancer susceptibility genes (Roche) and sequencing was performed on a MiSeq instrument. Detected variants were confirmed with Sanger sequencing. Results: Fifteen patients (18.75%) were heterozygous for at least one loss of function germline mutation in one of 52 (pancreatic) cancer susceptibility genes. We detected 18 class 5 variants in eleven genes: BRCA1 (n=1), BRCA2 (n=2), ATM (n=3), FANCM (n=2), PMS2 (n=1), MSH6 (n=1), FANCE (n=1), FANCD2 (n=1), CHEK2 (n=2), MUTYH (n=2) and NTHL1 (n=2). In addition, eight missense variants were predicted to affect function by in silico prediction programs in eight patients: ATM (n=3), ERCC4 (n=1), FANCA (n=1), BRIP1 (n=1), RAD51D (n=1) and POT1 (n=1). Conclusions: These preliminary results obtained in a relatively small cohort of cancer patients eligible for genetic testing because of a personal history of breast/colon/pancreatic cancer or melanoma and at least one close relative with pancreatic cancer, revealed inactivating mutations in cancer predisposition genes in 18.75% of the patients and certainly warrant a further extension of the study cohort. These findings warrant further segregation analysis in the families to evaluate their link with the different cancers and highlight the need for recommendations governing germline multi-gene panel testing of cancer patients with a personal or family history of pancreatic cancer.
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1 (1) , AB033
AB033. P003. Identification of germline mutations in cancer predisposition genes in patients with a personal and/or family history of pancreatic cancer
Background: Pancreatic cancer is estimated to have a familial background in 5–10%. Although the underlying genetic basis for most of the familial clustering remains elusive, multiple known hereditary syndromes and genes are associated with an increased risk of developing pancreatic cancer. Methods: We performed a retrospective genetic evaluation of 80 cancer patients with a presumed genetic predisposition for pancreatic cancer. The probands were selected from seven strata based on personal or family history of pancreatic cancer, breast and/or ovarian cancer, colon cancer or melanoma. Germline DNA was analyzed using a custom designed HEAT-Seq target panel of 52 (pancreatic) cancer susceptibility genes (Roche) and sequencing was performed on a MiSeq instrument. Detected variants were confirmed with Sanger sequencing. Results: Fifteen patients (18.75%) were heterozygous for at least one loss of function germline mutation in one of 52 (pancreatic) cancer susceptibility genes. We detected 18 class 5 variants in eleven genes: BRCA1 (n=1), BRCA2 (n=2), ATM (n=3), FANCM (n=2), PMS2 (n=1), MSH6 (n=1), FANCE (n=1), FANCD2 (n=1), CHEK2 (n=2), MUTYH (n=2) and NTHL1 (n=2). In addition, eight missense variants were predicted to affect function by in silico prediction programs in eight patients: ATM (n=3), ERCC4 (n=1), FANCA (n=1), BRIP1 (n=1), RAD51D (n=1) and POT1 (n=1). Conclusions: These preliminary results obtained in a relatively small cohort of cancer patients eligible for genetic testing because of a personal history of breast/colon/pancreatic cancer or melanoma and at least one close relative with pancreatic cancer, revealed inactivating mutations in cancer predisposition genes in 18.75% of the patients and certainly warrant a further extension of the study cohort. These findings warrant further segregation analysis in the families to evaluate their link with the different cancers and highlight the need for recommendations governing germline multi-gene panel testing of cancer patients with a personal or family history of pancreatic cancer.
- Open Access
- 17 November 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 912
BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
Current knowledge of the aetiology of hereditary breast cancer in the four main South African population groups (black, coloured, Indian and white) is limited. Risk assessments in the black, coloured and Indian population groups are challenging because of restricted information regarding the underlying genetic contributions to inherited breast cancer in these populations. We focused this study on premenopausal patients (diagnosed with breast cancer before the age of 50; n = 78) and triple negative breast cancer (TNBC) patients (n = 30) from the four South African ethnic groups. The aim of this study was to determine the frequency and spectrum of germline mutations in BRCA1, BRCA2 and PALB2 and to evaluate the presence of the CHEK2 c.1100delC allele in these patients. In total, 108 South African breast cancer patients underwent mutation screening using a Next-Generation Sequencing (NGS) approach in combination with Multiplex Ligation-dependent Probe Amplification (MLPA) to detect large rearrangements in BRCA1 and BRCA2. In 13 (12 %) patients a deleterious mutation in BRCA1/2 was detected, three of which were novel mutations in black patients. None of the study participants was found to have an unequivocal pathogenic mutation in PALB2. Two (white) patients tested positive for the CHEK2 c.1100delC mutation, however, one of these also carried a deleterious BRCA2 mutation. Additionally, six variants of unknown clinical significance were identified (4 in BRCA2, 2 in PALB2), all in black patients. Within the group of TNBC patients, a higher mutation frequency was obtained (23.3 %; 7/30) than in the group of patients diagnosed before the age of 50 (7.7 %; 6/78). This study highlights the importance of evaluating germline mutations in major breast cancer genes in all of the South African population groups. This NGS study shows that mutation analysis is warranted in South African patients with triple negative and/or in premenopausal breast cancer.
- 17 November 2015
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 912
Open AccessBRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer
Current knowledge of the aetiology of hereditary breast cancer in the four main South African population groups (black, coloured, Indian and white) is limited. Risk assessments in the black, coloured and Indian population groups are challenging because of restricted information regarding the underlying genetic contributions to inherited breast cancer in these populations. We focused this study on premenopausal patients (diagnosed with breast cancer before the age of 50; n = 78) and triple negative breast cancer (TNBC) patients (n = 30) from the four South African ethnic groups. The aim of this study was to determine the frequency and spectrum of germline mutations in BRCA1, BRCA2 and PALB2 and to evaluate the presence of the CHEK2 c.1100delC allele in these patients. In total, 108 South African breast cancer patients underwent mutation screening using a Next-Generation Sequencing (NGS) approach in combination with Multiplex Ligation-dependent Probe Amplification (MLPA) to detect large rearrangements in BRCA1 and BRCA2. In 13 (12 %) patients a deleterious mutation in BRCA1/2 was detected, three of which were novel mutations in black patients. None of the study participants was found to have an unequivocal pathogenic mutation in PALB2. Two (white) patients tested positive for the CHEK2 c.1100delC mutation, however, one of these also carried a deleterious BRCA2 mutation. Additionally, six variants of unknown clinical significance were identified (4 in BRCA2, 2 in PALB2), all in black patients. Within the group of TNBC patients, a higher mutation frequency was obtained (23.3 %; 7/30) than in the group of patients diagnosed before the age of 50 (7.7 %; 6/78). This study highlights the importance of evaluating germline mutations in major breast cancer genes in all of the South African population groups. This NGS study shows that mutation analysis is warranted in South African patients with triple negative and/or in premenopausal breast cancer.
- 1 January 2015
- Published by Springer Nature
- Vol. 867, 263-275
Non Coding RNA Molecules as Potential Biomarkers in Breast Cancer
The pursuit of minimally invasive biomarkers is a challenging but exciting area of research. Clearly, such markers would need to be sensitive and specific enough to aid in the detection of breast cancer at an early stage, would monitor progression of the disease, and could predict the individual patient’s response to treatment. Unfortunately, to date, markers with such characteristics have not made it to the clinic for breast cancer. Past years, many studies indicated that the non-coding part of our genome (the so called ‘junk’ DNA), may be an ideal source for these biomarkers. In this chapter, the potential use of microRNAs and long non-coding RNAs as biomarkers will be discussed.
- 1 January 2015
- Published by Springer Nature
- Vol. 867, 263-275
Non Coding RNA Molecules as Potential Biomarkers in Breast Cancer
The pursuit of minimally invasive biomarkers is a challenging but exciting area of research. Clearly, such markers would need to be sensitive and specific enough to aid in the detection of breast cancer at an early stage, would monitor progression of the disease, and could predict the individual patient’s response to treatment. Unfortunately, to date, markers with such characteristics have not made it to the clinic for breast cancer. Past years, many studies indicated that the non-coding part of our genome (the so called ‘junk’ DNA), may be an ideal source for these biomarkers. In this chapter, the potential use of microRNAs and long non-coding RNAs as biomarkers will be discussed.
- 1 November 2014
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 69 (11) , 659-660
Breast-Cancer Risk in Families With Mutations in PALB2
- 1 November 2014
- Published by Wolters Kluwer Health in Obstetrical & Gynecological Survey
- Vol. 69 (11) , 659-660
Breast-Cancer Risk in Families With Mutations in PALB2
- Open Access
- 30 September 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (9) , e25531
Practical Tools to Implement Massive Parallel Pyrosequencing of PCR Products in Next Generation Molecular Diagnostics
Despite improvements in terms of sequence quality and price per basepair, Sanger sequencing remains restricted to screening of individual disease genes. The development of massively parallel sequencing (MPS) technologies heralded an era in which molecular diagnostics for multigenic disorders becomes reality. Here, we outline different PCR amplification based strategies for the screening of a multitude of genes in a patient cohort. We performed a thorough evaluation in terms of set-up, coverage and sequencing variants on the data of 10 GS-FLX experiments (over 200 patients). Crucially, we determined the actual coverage that is required for reliable diagnostic results using MPS, and provide a tool to calculate the number of patients that can be screened in a single run. Finally, we provide an overview of factors contributing to false negative or false positive mutation calls and suggest ways to maximize sensitivity and specificity, both important in a routine setting. By describing practical strategies for screening of multigenic disorders in a multitude of samples and providing answers to questions about minimum required coverage, the number of patients that can be screened in a single run and the factors that may affect sensitivity and specificity we hope to facilitate the implementation of MPS technology in molecular diagnostics.
- 30 September 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (9) , e25531
Open AccessPractical Tools to Implement Massive Parallel Pyrosequencing of PCR Products in Next Generation Molecular Diagnostics
Despite improvements in terms of sequence quality and price per basepair, Sanger sequencing remains restricted to screening of individual disease genes. The development of massively parallel sequencing (MPS) technologies heralded an era in which molecular diagnostics for multigenic disorders becomes reality. Here, we outline different PCR amplification based strategies for the screening of a multitude of genes in a patient cohort. We performed a thorough evaluation in terms of set-up, coverage and sequencing variants on the data of 10 GS-FLX experiments (over 200 patients). Crucially, we determined the actual coverage that is required for reliable diagnostic results using MPS, and provide a tool to calculate the number of patients that can be screened in a single run. Finally, we provide an overview of factors contributing to false negative or false positive mutation calls and suggest ways to maximize sensitivity and specificity, both important in a routine setting. By describing practical strategies for screening of multigenic disorders in a multitude of samples and providing answers to questions about minimum required coverage, the number of patients that can be screened in a single run and the factors that may affect sensitivity and specificity we hope to facilitate the implementation of MPS technology in molecular diagnostics.
- Open Access
- 20 May 2010
- Published by Springer Nature in BMC Bioinformatics
- Vol. 11 (1) , 269
Analysing 454 amplicon resequencing experiments using the modular and database oriented Variant Identification Pipeline
Next-generation amplicon sequencing enables high-throughput genetic diagnostics, sequencing multiple genes in several patients together in one sequencing run. Currently, no open-source out-of-the-box software solution exists that reliably reports detected genetic variations and that can be used to improve future sequencing effectiveness by analyzing the PCR reactions.
- 20 May 2010
- Published by Springer Nature in BMC Bioinformatics
- Vol. 11 (1) , 269
Open AccessAnalysing 454 amplicon resequencing experiments using the modular and database oriented Variant Identification Pipeline
Next-generation amplicon sequencing enables high-throughput genetic diagnostics, sequencing multiple genes in several patients together in one sequencing run. Currently, no open-source out-of-the-box software solution exists that reliably reports detected genetic variations and that can be used to improve future sequencing effectiveness by analyzing the PCR reactions.